Comorbidities and confusion: addressing COVID-19 vaccine access and information challenges
DOI:
https://doi.org/10.33321/cdi.2024.48.33Keywords:
COVID-19, chronic disease management, communication and marketing, epidemic and pandemic preparedness, health policyAbstract
Objective
Early in the coronavirus disease 2019 (COVID-19) pandemic, evidence emerged that individuals with chronic and immunocompromising conditions faced increased risk of severe infection, including death. The Australian Government and public health authorities prioritised these citizens’ access to vaccines, including them in phase 1b of the rollout from 22 March 2021. Given the rapidly evolving knowledge and advice, we sought to understand what people with comorbidities understood about their eligibility, where they obtained information, and their experiences interfacing with the program.
Methods
Through the mixed methods project Coronavax, we conducted semi-structured in-depth interviews with eight West Australians aged under 60 who signed up to the study’s webpage and declared comorbidities pertinent to serious COVID-19 complications. Interviews were conducted during January–April 2022, audio-recorded, transcribed in full, and analysed in NVivo 20 using inductive methods. We validated participants’ accounts of state government actions with a representative in person and in writing.
Results
We identified access and informational barriers – and a lack of understanding – about vaccine eligibility amongst West Australians with comorbidities. Amid a rapidly changing landscape of knowledge with subsequent policy implications, this group received insufficient information for their needs for understanding their place in the immunisation program.
Conclusions
Fast-changing knowledge about vaccines creates communication challenges for government and health professionals. We identify an urgent need to develop, pilot, and evaluate strategies for providing vaccination information in routine and pandemic settings.
Downloads
References
Centers for Disease and Control Prevention (CDC). Underlying medical conditions associated with higher risk for severe COVID-19: Information for healthcare professionals. [Webpage.] Atlanta: United States Government Department of Health and Human Services, CDC; 15 June 2022. [Accessed on 18 November 2022.] Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.
Liu B, Spokes P, He W, Kaldor J. High risk groups for severe COVID-19 in a whole of population cohort in Australia. BMC Infect. Dis. 2021;21(1):685. doi: https://doi.org/10.1186/s12879-021-06378-z.
Parkinson A, Matenge S, Desborough J, Hall Dykgraaf S, Ball L, Wright M et al. The impact of COVID-19 on chronic disease management in primary care: lessons for Australia from the international experience. Med J Aust. 2022;216(9):445–8. doi: https://doi.org/10.5694/mja2.51497.
Seale H, McFadden K, Dyda A, Kaufman J, Heywood A. The pendulum has swung: How do we ensure a life course approach to immunisation in Australia? Front Public Health. 2021;9:801176. doi: https://doi.org/10.3389/fpubh.2021.801176.
McFadden K, Heywood A, Dyda A, Kaufman J, Seale H. Minimising missed opportunities to promote and deliver immunization services to middle and older age adults: can hospital-based programs be a solution? Vaccine. 2021;39(26):3467–72. doi: https://doi.org/10.1016/j.vaccine.2021.05.027.
Australian Government Department of Health and Aged Care. ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns. [Internet.] Canberra: Australian Government Department of Health and Aged Care; 8 April 2021. [Accessed on 22 November 2022.] Available from: https://www.health.gov.au/news/atagi-statement-on-astrazeneca-vaccine-in-response-to-new-vaccine-safety-concerns.
Patel C, Danchin M, Sheel M. Over-50s can now get their COVID vaccine: What do they need to know? [Online article.] Melbourne: Royal Australian College of General Practitioners (RACGP), News GP; 3 May 2021. [Accessed on 6 April 2023.] Available from: https://www1.racgp.org.au/newsgp/clinical/australians-over-50-can-now-get-their-covid-vaccin.
Australian Government Department of Health and Aged Care. ATAGI statement about the need for additional doses of COVID-19 vaccines. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 23 September 2021. [Accessed on 22 November 2022.] Available from: https://www.health.gov.au/news/atagi-statement-about-the-need-for-additional-doses-of-covid-19-vaccines.
Attwooll J. ATAGI says third vaccine dose ‘likely’ for certain cohorts. [Online article.] Melbourne: RACGP, News GP; 23 September 2021. [Accessed on 22 November 2022.] Available from: https://www1.racgp.org.au/newsgp/clinical/atagi-says-third-vaccine-dose-likely-for-certain-c.
Evans J. ATAGI says ‘severely’ immunocompromised people should get a third COVID-19 vaccine shot. [News article.] Sydney: Australian Broadcasting Corporation, ABC News; 8 October 2021. [Accessed on 22 November 2022.] Available from: https://www.abc.net.au/news/2021-10-08/covid-19-vaccine-booster-shots-for-immunocompromised/100523636.
Attwell K, Carlson S, Tchilingirian J, Harper T, McKenzie L, Roberts L et al. Coronavax: preparing community and government for COVID-19 vaccination: a research protocol for a mixed methods social research project. BMJ Open. 2021;11(6):e049356. doi: https://doi.org/10.1136/bmjopen-2021-049356.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi: https://doi.org/10.1016/j.jbi.2008.08.010.
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: https://doi.org/10.1016/j.jbi.2019.103208.
McKenzie L, Attwell K. ‘I’m provax’: pro-vaccination personal histories and socialities of older Australians in the COVID-19 pandemic. Sociol Health Illn. 2023;45(7):1441–61. doi: https://doi.org/10.1111/1467-9566.13640.
Roberts L, Deml MJ, Attwell K. ‘COVID is coming, and I’m bloody scared’: how adults with co-morbidities’ threat perceptions of COVID-19 shape their vaccination decisions. Int J Environ Res Public Health. 2023;20(4):2953. doi: https://doi.org/10.3390/ijerph20042953.
National Centre for Immunisation Research and Surveillance (NCIRS). Check your personal risk profile. [Webpage.] Sydney: NCIRS; 2022. [Accessed on 22 November 2022.] Available from: https://www.ncirs.org.au/covid-19-decision-aid-for-adults/profile.
Kidney Health Australia. Coronavirus (COVID-19) and your kidneys. [Webpage.] Melbourne: Kidney Health Australia; 2022. [Accessed on 18 July 2022.] Available from: https://kidney.org.au/your-kidneys/know-your-kidneys/covid-19-and-your-kidneys.
Cancer Australia, Australian Government. COVID-19 vaccines and cancer. [Webpage.] Canberra: Cancer Australia; 2022. [Accessed on 22 November 2022.] Available from: https://www.canceraustralia.gov.au/covid-19-vaccine-and-cancer.
Quinn A, White A, Abbatangelo-Gray J, McCarron S, Schub T, Ratzan SC. COVID-19 communication campaigns for vaccination: an assessment with perspectives for future equity-centered public health efforts. J Health Commun. 2023;28(sup1):54–66. doi: https://doi.org/10.1080/10810730.2023.2208529.
Vann JC, Jacobson RM, Coyne‐Beasley T, Asafu‐Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018;1(1):CD003941. doi: https://doi.org/10.1002/14651858.CD003941.pub3.
Ridda I, Lindley IR, Gao Z, McIntyre P, Macintyre CR. Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people. Vaccine. 2008;26(44):5633–40. doi: https://doi.org/10.1016/j.vaccine.2008.07.070.
McFadden K, Seale H. A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults. Vaccine. 2021;39(4):658–66. doi: https://doi.org/10.1016/j.vaccine.2020.12.042.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
